Cerevance
Cambridge
United Kingdom
About Cerevance
Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company will use a new technology.69 articles about Cerevance
-
Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention
6/8/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, announced that Craig Thompson, chief executive officer of Cerevance, will participate in a panel discussion during the 2022 BIO International Convention being held in San Diego, CA, June 13-16.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
4/19/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the appointment of Craig Thompson to chief executive officer.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Cerevance reported positive clinical trial results for CVN424, an experimental treatment for Parkinson’s disease.
-
Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
3/31/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the completion of its Phase 2 clinical trial of CVN424, the company’s first-in-class, once-a-day, orally-delivered compound in development for the treatment of Parkinson’s disease.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766Study will evaluate safety and pharmacokinetics of potential treatment for psychiatric disorders
1/25/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the dosing of the first human subjects in a Phase 1 clinical trial of its compound, CVN766.
-
Many big companies, including Amgen, Moderna, Roche and Novartis, had already decided not to attend in-person and the sentiment was leaning that way.
-
BioSpace Movers & Shakers, Sept. 10
9/10/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors
9/8/2021
Cerevance today announced the appointment of Mike Poole, M.D., FACP, to Cerevance’s Board of Directors.
-
BioSpace Movers & Shakers, Feb. 12
2/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Cerevance Appoints Naidong Ye, Ph.D., As Vice President and Head of Chemistry, Manufacturing and ControlsWill lead scale-up and production as Cerevance advances multiple clinical-stage programs
2/10/2021
Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of Naidong Ye, Ph.D., a seasoned chemist with extensive pharmaceutical industry experience, as vice president and head of chemistry, manufacturing and controls (CMC).
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Cerevance Appoints Carrie Ann Cook As Chief Business Officer
2/1/2021
Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of Carrie Ann Cook, a global business development executive with more than 20 years of experience in the pharmaceutical industry, as chief business officer effective February 1, 2021
-
BioSpace spoke to executives from four companies about their expectations for the conference and the coming year.
-
BioSpace Movers & Shakers, Dec. 11
12/11/2020
Biopharma and life science companies and organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Cerevance Appoints David Lubner to Board of DirectorsLife sciences industry veteran brings more than 25 years of financial and operational experience
12/8/2020
Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors. Mr. Lubner most recently served as executive vice president and chief financial officer of Ra Pharma, which was acquired by UCB in April of this year. Before joining Ra Pharma, he served
-
Despite a number of anti-psychotic medications available, there are no approved drugs to address underlying cognitive development issues. Cerevance aims to change that.
-
Cerevance’s CVN058 Achieves Primary Endpoint in Phase Ib Schizophrenia Cognition StudyPositive results with biomarker of cerebral cortical dysfunction raises hope for treatment of cognitive impairment associated with schizophrenia
11/16/2020
Cerevance, a private drug discovery and development company focused on brain diseases, today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS).